Gain Therapeutics (GANX) News Today → What President Biden's new law means for investors (From Stansberry Research) (Ad) Free GANX Stock Alerts $2.57 -0.06 (-2.28%) (As of 10:35 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 2:50 AM | americanbankingnews.comChardan Capital Weighs in on Gain Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:GANX)May 18 at 5:46 AM | americanbankingnews.comGain Therapeutics, Inc. (NASDAQ:GANX) Forecasted to Post FY2025 Earnings of ($1.25) Per ShareMay 18 at 2:18 AM | americanbankingnews.comQ2 2024 Earnings Forecast for Gain Therapeutics, Inc. (NASDAQ:GANX) Issued By HC WainwrightMay 17 at 4:38 AM | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)May 15, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial PerformanceMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial HealthMay 14, 2024 | globenewswire.comGain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical ProgressApril 24, 2024 | markets.businessinsider.comGain Therapeutics Announces Positive Phase 1 Results For GT-02287 In GBA1 Parkinson's Disease TrialApril 24, 2024 | finance.yahoo.comGain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseApril 24, 2024 | globenewswire.comGain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's DiseaseApril 23, 2024 | marketbeat.comGain Therapeutics (NASDAQ:GANX) Receives Outperform Rating from OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $9.00 price objective on shares of Gain Therapeutics in a research note on Tuesday.April 20, 2024 | investing.comGain Therapeutics Inc (GANX)April 17, 2024 | finance.yahoo.comHere's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom FisherApril 8, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerApril 8, 2024 | markets.businessinsider.comGain Therapeutics Appoints Gene Mack As CFO; Stock FallsApril 8, 2024 | globenewswire.comGain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerApril 4, 2024 | msn.comFormer Gildan CEO considered acquisition of Hanesbrands - BloombergApril 2, 2024 | insidertrades.comGain Therapeutics, Inc. (NASDAQ:GANX) Director Buys $115,800.00 in StockApril 1, 2024 | finance.yahoo.comDirector Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial OutlookApril 1, 2024 | finance.yahoo.comGain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerApril 1, 2024 | marketbeat.comGain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Gain Therapeutics in a report on Monday.March 31, 2024 | marketbeat.comShort Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Increases By 16.4%Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 156,700 shares, a growth of 16.4% from the February 29th total of 134,600 shares. Based on an average trading volume of 171,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.9% of the shares of the company are sold short.March 28, 2024 | markets.businessinsider.comOptimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287March 27, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 26, 2024 | globenewswire.comGain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateMarch 15, 2024 | globenewswire.comGain Therapeutics to Present at Public Ventures Discovery DayMarch 5, 2024 | msn.comEXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's DiseaseMarch 5, 2024 | finance.yahoo.comGain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseFebruary 27, 2024 | finance.yahoo.comGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseFebruary 27, 2024 | globenewswire.comGain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's DiseaseFebruary 23, 2024 | benzinga.comGain Therapeutics Stock (NASDAQ:GANX), Short Interest ReportFebruary 17, 2024 | finance.yahoo.comGANX Mar 2024 7.500 callFebruary 16, 2024 | marketbeat.comGain Therapeutics, Inc. (NASDAQ:GANX) Sees Large Growth in Short InterestGain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 121,300 shares, an increase of 17.2% from the January 15th total of 103,500 shares. Based on an average daily volume of 144,800 shares, the short-interest ratio is currently 0.8 days. Currently, 0.7% of the company's stock are short sold.February 16, 2024 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst InsightFebruary 14, 2024 | finance.yahoo.comGain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightFebruary 14, 2024 | globenewswire.comGain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst InsightFebruary 7, 2024 | markets.businessinsider.comBuy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson’s Candidate GT-02287February 6, 2024 | marketwatch.comAmgen 4Q Revenue Surges as Acquisition Boosts ResultsFebruary 6, 2024 | finance.yahoo.comGain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseFebruary 6, 2024 | finance.yahoo.comUPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Gain Therapeutics’ Promising GT-02287 Advances Towards Key Clinical Milestones in Parkinson’s Disease TreatmentFebruary 1, 2024 | seekingalpha.comAmgen: Debt-Funded Buybacks Constrains Future Gains Per ShareJanuary 31, 2024 | finance.yahoo.comGain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational UpdateJanuary 24, 2024 | finance.yahoo.comGain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should KnowJanuary 17, 2024 | seekingalpha.comGANX Gain Therapeutics, Inc.January 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Gain Therapeutics’ GT-02287 Shows Promise in Parkinson’s Disease PipelineJanuary 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Gain Therapeutics (GANX) Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some GANX Media Mentions By Week GANX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GANX News Sentiment▼0.910.42▲Average Medical News Sentiment GANX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GANX Articles This Week▼171▲GANX Articles Average Week Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Eyenovia News CASI Pharmaceuticals News VYNE Therapeutics News Unicycive Therapeutics News HCW Biologics News Ocuphire Pharma News Xilio Therapeutics News NextCure News Lexaria Bioscience News Cara Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GANX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold4 Cryptos BETTER than BitcoinTrue Market InsidersDoes this make you sick?Allegiance GoldBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
